Moderna (MRNA) Capital Expenditures (2018 - 2026)

Moderna (MRNA) has reported Capital Expenditures for 9 consecutive years, with $37.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 1133.33% year-over-year to $37.0 million in Q2 2026; TTM through Jun 2026 was $171.0 million, a 78.44% decrease from a year earlier, with the FY2025 full-year figure at $192.0 million, down 81.73% from the prior year.
• Capital Expenditures was $37.0 million for Q2 2026 at Moderna, down from $62.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $522.0 million in Q4 2024 and troughed at $3.0 million in Q2 2025.
• A 5-year average of $136.1 million and a median of $115.0 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slumped 98.35% in 2025 and surged 1133.33% in 2026, its largest moves.
• Over 5 years, Capital Expenditures stood at $92.0 million in 2022, then soared by 139.13% to $220.0 million in 2023, then soared by 137.27% to $522.0 million in 2024, then tumbled by 92.53% to $39.0 million in 2025, then decreased by 5.13% to $37.0 million in 2026.
• The last three Capital Expenditures figures came in at $37.0 million (Q2 2026), $62.0 million (Q1 2026), and $39.0 million (Q4 2025), per Business Quant data.